News & Updates
Filter by Specialty:
Sotrovimab of no help in attenuating COVID-19 severity in face of Omicron BA.2 subvariant
26 Sep 2022
Treatment with sotrovimab does not appear to confer protection against severe forms of COVID-19 in a setting dominated by the Omicron BA.2 subvariant, a study has found.
Sotrovimab of no help in attenuating COVID-19 severity in face of Omicron BA.2 subvariant
26 Sep 2022Mirabegron benefits men with OAB, erectile dysfunction
26 Sep 2022
The selective β3-AR agonist mirabegron appears to confer benefits for both overactive bladder (OAB) symptoms and erectile dysfunction (ED) in some patients without compromising safety, as reported in a study.
Mirabegron benefits men with OAB, erectile dysfunction
26 Sep 2022Elobixibat affords metabolic benefits in type 2 diabetes
25 Sep 2022
In type 2 diabetes (T2D) patients with constipation, treatment with elobixibat alleviates constipation while improving glucose metabolism and lowering serum low-density lipoprotein cholesterol (LDL-C) and arachidonic acid (AA) levels, according to the results of a single-arm pilot study.